A detailed history of Man Group PLC transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Man Group PLC holds 142,426 shares of PCVX stock, worth $11.4 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
142,426
Previous 14,551 878.81%
Holding current value
$11.4 Million
Previous $1.66 Million 601.87%
% of portfolio
0.03%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$80.97 - $117.93 $10.4 Million - $15.1 Million
127,875 Added 878.81%
142,426 $11.7 Million
Q3 2024

Nov 14, 2024

BUY
$70.52 - $117.12 $1.03 Million - $1.7 Million
14,551 New
14,551 $1.66 Million
Q1 2023

May 15, 2023

BUY
$36.27 - $47.2 $924,594 - $1.2 Million
25,492 New
25,492 $955,000

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $4.73B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Man Group PLC Portfolio

Follow Man Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.